CD274 and neoplasm: Combining NHS-IL12 with an anti-PD-L1 antibody, one would anticipate enrichment of the known immune-related actions of this strong TH1 cytokine while blocking the immune suppression within the tumor microenvironment through the interruption of the PD-1/PD-L1 axis.